Asia-Pacific Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End-user and Country – ResearchAndMarkets.com

Asia

DUBLIN–(BUSINESS WIRE)–Jun 29, 2020–

The “Asia-Pacific Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com‘s offering.

Asia-Pacific artificial intelligence (AI) in drug discovery market will grow by 33.2% over 2020-2026 with a total addressable market cap of $2.78 billion, owing to fast adoption of AI technology in pharmaceutical industry and drug development.

The report provides historical market data for 2015-2019, revenue estimates for 2020, and forecasts from 2021 till 2026.

Highlighted with 34 tables and 53 figures, this 121-page report is based on a comprehensive research of the entire Asia Pacific AI in drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.

In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific AI in drug discovery market in every aspect of the classification from perspectives of Offering, Technology, Drug Type, Therapeutic Area, Application, End User, and Country.

Based on offering, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.

  • Software
  • Service

Based on technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.

  • Deep Learning
  • Supervised Learning
  • Reinforcement Learning
  • Unsupervised Learning
  • Other Technologies

Based on drug type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.

  • Large-molecule Drugs
  • Small-molecular Drugs

Based on therapeutic area, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.

  • Oncology
  • Neurodegenerative Diseases
  • Cardiovascular Disease
  • Metabolic Diseases
  • Other Therapeutic Areas

Based on application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.

  • Information & Data Analysis
  • Drug Design
  • Drug Evaluation
  • Clinical Trials
  • Other Applications

Based on end user, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 (historical and forecast) included in each section.

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations

Geographically, the following national/local markets are fully investigated:

  • Japan
  • China
  • South Korea
  • Australia
  • India
  • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

For each of the aforementioned countries, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Technology, Therapeutic Area, and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia-Pacific AI in drug discovery market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players

  • Atomwise, Inc.
  • BenevolentAI
  • Berg LLC
  • Bioage
  • BIOAGE
  • Cloud Pharmaceuticals, Inc.
  • Cyclica
  • Deep Genomics
  • Envisagenics
  • Exscientia
  • Google
  • IBM Corporation
  • Insilico Medicine
  • Microsoft Corporation
  • Numedii, Inc.
  • Numerate
  • NVIDIA Corporation
  • Owkin, Inc.
  • Twoxar, Incorporated
  • Verge Genomics
  • Xtalpi, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/hyu6yd

View source version on businesswire.com:https://www.businesswire.com/news/home/20200629005628/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD: ASIA PACIFIC

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 06/29/2020 11:46 AM/DISC: 06/29/2020 11:46 AM

http://www.businesswire.com/news/home/20200629005628/en

© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Leave a Reply